Artificial Intelligence
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included at the 17th Annual WORLDSymposium™ 2021, to be held virtually February 8-12, 2021.
Oral Platform Presentations:
- Direct intercellular cross-correction of α-galactosidase-A deficiency in Fabry disease podocytes through tunneling nanotubes in a mixed cell culture model – Behzad Najafian, MD, Department of Pathology, University of Washington, Seattle, WA, USA (Monday, February 8 at 1:12 p.m. EST)
- Single-dose AAV9-CLN6 gene transfer slows the decline in motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6: Interim results from phase 1/2 trial – Emily de los Reyes, MD, Pediatric Neurology, Nationwide Children’s Hospital, Columbus, OH, USA (Wednesday, February 10 at 11:24 a.m. EST)
- Utilization of artificial intelligence to identify undiagnosed Fabry disease patients: Development of a validated machine learning model – John Jefferies, MD, MPH, Division of Cardiovascular Disease, University of Tennessee Health Science Center, Memphis, TN, USA (Thursday, February 11 at 1:00 p.m. EST)
ePoster Sessions:
Monday, February 8, 2:30-3:30 p.m. EST
- Direct intercellular cross-correction of α-galactosidase-A deficiency in Fabry disease podocytes through tunneling nanotubes in a mixed cell culture model – Behzad Najafian, MD, Department of Pathology, University of Washington, Seattle, WA, USA (Poster #169)
Tuesday, February 9, 2:30-3:30 p.m. EST
- Functional analysis and clinical curation of human acid alpha glucosidase (GAA) variants of unknown significance (VUS) screened from infants diagnosed with Pompe disease via newborn screening (NBS) – Shelly Goomber, PhD, Division of Medical Genetics, Duke University Medical Center, Durham, NC, USA (Poster #87)
- Development of a Fabry disease screening tool for chronic pain patients – step 1: Categorization based on phenotypic risk profiles – Michael A. Ueberall, MD, Pediatric Neurology, Institute of Neurological Sciences, Nurnberg, Germany (Poster #256)
Wednesday, February 10, 2:30-3:30 p.m. EST
- Long-term treatment with migalastat 150 mg every other day is associated with sustained cardiac efficacy and is well tolerated – Ulla Feldt-Rasmussen MD, DMSc, Department of Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (Poster #70)
- Migalastat 150 mg every other day achieves bioequivalent exposures in adolescent and adult patients with Fabry disease – Uma Ramaswami, MD, Lysosomal Storage Disease Unit, Royal Free London NHS Foundation Trust, London, UK (Poster #210)
Thursday, February 11, 2:30-3:30 p.m. EST
- Utilization of artificial intelligence to identify undiagnosed Fabry disease patients: Development of a validated machine learning model – John Jefferies, MD, MPH, Division of Cardiovascular Disease, University of Tennessee Health Science Center, Memphis, TN, USA (Poster #107)
- Migalastat clinical dose is highly extracted by hemodialysis and hemodiafiltration – Franklin Johnson, MS, Clinical Pharmacology and Pharmacokinetics, Amicus Therapeutics, Inc., Cranbury, NJ, USA (Poster #108)
- Development of a novel gene therapy for Fabry disease: Engineered alpha-galactosidase A transgene for improved stability – Tobias Willer, Principal Investigator, Amicus Therapeutics, Inc., Philadelphia, PA, USA (Poster #272)
Friday, February 12, 2:30-3:30 p.m. EST
- An open-label, phase 1/2a, AAV9-CLN3 gene transfer clinical trial for juvenile neuronal ceroid lipofuscinosis – Emily de los Reyes, MD, Pediatric Neurology, Nationwide Children’s Hospital, Columbus, OH, USA (Poster #LB-10)
- Long-term renal efficacy and incidence of Fabry-associated clinical events in treatment-naive and enzyme replacement therapy-experienced female patients receiving migalastat for Fabry disease up to 8.5 years – Heather A. Lau, MD, Division of Neurogenetics, New York University, NY, USA (Poster #LB-28)
The goal of WORLDSymposium is to provide an interdisciplinary forum to explore and discuss specific areas of interest, research and clinical applicability related to lysosomal diseases. Each year, WORLDSymposium hosts a scientific meeting presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases. This symposium is designed to help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases, identify areas requiring additional basic and clinical research, public policy and regulatory attention, and identify the latest findings in the natural history of lysosomal diseases. For more information please visit www.worldsymposia.org.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product. In addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe, Japan, the US and other geographies or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies and manufacturing. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Statements regarding corporate financial guidance and financial goals and the attainment of such goals. With respect to statements regarding projections of the Company’s revenue and cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 and the Quarterly Report filed on Form 10-Q for the quarter ended September 30, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
[email protected]
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
[email protected]
(609) 662-5079
FOLD–G
Artificial Intelligence
Northern Data Group platform, Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
The location expands on an adjacent 300MW site, purchased in December 2023 The site comes with an ERCOT-approved interconnect of 300MWConstruction already underway, with long-lead time items secured and energization scheduled for early 2025FRANKFURT, Germany, May 24, 2024 /PRNewswire/ — Peak Mining, part of the Northern Data Group , announces the purchase of a second 300MW ERCOT-approved site in Corpus Christi, Texas. The location is adjacent to the 300MW mining facility that is already under construction. The site also provides energy in the attractive low-cost power zone of Load Zone South of the ERCOT grid, known for its abundance of renewable (wind) energy.
The investment represents a significant step forward in Northern Data Group’s investment strategy, cementing expansion plans well beyond the current 2024 financial year.
The new site enables Peak Mining to accelerate its expansion plans to become one of the largest bitcoin miners globally. The company will be deploying indoor, custom-designed, fully-integrated and liquid-cooled HPC data center systems to drastically improve deployment time and infrastructure cost, bringing Peak Mining to a leading position in the industry and preparing it for the future of HPC compute.
Saxet Infrastructure Group (“Saxet”) will act as construction manager for the design, build and energization of the substation. The Saxet team brings a strong track record of project management and deep expertise with the construction of HPC infrastructure.
Niek Beudeker, Managing Director of Northern Data Group Platform, Peak Mining, commented:
“The purchase of this second large site will significantly shorten our time to hashing and kick off one of the fastest mining expansions globally. We now have almost 700MW of sites in active development, that when fully fitted with our latest-generation hardware, could potentially provide up to 40EH of hash rate.”
Aroosh Thillainathan, Northern Data Group’s Chief Executive Officer, commented:
“This second data center location demonstrates how Northern Data Group is able to harness the power and opportunity of HPC. Sustainability has been at the core of this further expansion into the US and thanks to the center’s ERCOT approved status, we will be able to scale our operations at speed, as the demand for digital assets continues to grow.”
Steven Quisenberry, Chief Executive Officer at Saxet Infrastructure Group, commented:
We are excited to support Northern Data Group’s expansion in the ERCOT market and specifically to welcome them to the Corpus Christi area. The combination of base load industrial demand and significant renewable resources creates a unique opportunity for their portfolio. This is a terrific example of one of the largest, most advanced liquid cooled data centers in North America and we are proud to partner with Northern Data Group to bring their data center online.
Northern Data Group was advised on the transaction by Katten Muchin Rosenman LLP (Legal Counsel) and BitOoda Technologies LLC.
About Peak Mining
Peak Mining, part of the Northern Data Group, is powering the future of the blockchain network. We deliver industry-leading operating and energy efficiency in bitcoin mining through the latest hardware alongside innovative technology and infrastructure. With our mining heritage dating back to 2013, we’ve been innovating for over a decade and have been at the forefront of the industry ever since. Our high-quality infrastructure is purpose-built to power the mining network, and we’re driven to continuously find new efficiencies driving value for our investors. We’re delivering long term value in more responsible ways.
About Northern Data Group
Northern Data Group (ETR: NB2) is a leading provider of High Performance Computing (HPC) solutions to businesses and research institutions, utilizing GPU- and ASIC-based solutions. Our flexible compute power fuels innovation in our three core business platforms: Taiga Cloud, Ardent Data Centers, and Peak Mining. Through our HPC solutions, we pioneer ambitious computing innovation that drives progress in the AI, ML and Generative AI industries. Our close collaboration with industry-leading manufacturers including Gigabyte, AMD, and NVIDIA is fundamental to the acceleration of innovation across sectors including life sciences, financial services, and energy.
View original content:https://www.prnewswire.co.uk/news-releases/northern-data-group-platform-peak-mining-announces-purchase-of-a-second-300mw-data-center-location-in-corpus-christi-texas-302154571.html
Artificial Intelligence
Omnicom Media Group Expands Its Partnership with Lumen, Further Advancing Attention-Based Planning Capabilities Across Its Regions
LONDON, May 24, 2024 /PRNewswire/ — Omnicom Media Group (OMG) the media services division of leading global marketing and corporate communications holding company Omnicom Group Inc (NYSE: OMC) is expanding its market intelligence relationship with leading attention research company Lumen to now include data integration.
Under the terms of the agreement, attention data from the Lumen’s Attention Measurement Platform – which includes expected average viewing time and attentive seconds per thousand impressions – will be integrated into channel planning tools and processes within Omni, the open operating system that supports all Omnicom agencies. The addition of the Lumen attention benchmarks further advances OMG’s industry-leading attention-based planning capabilities, adding additional depth and breadth of insights to the existing attention datasets within Omni that enable attention to be leveraged as a KPI for media decisioning and creative optimization across OMG agencies OMD, PHD and Hearts & Science.
Over the past eight years, OMG has partnered with Lumen and other leading experts in attention measurement on hundreds of studies involving over 640,000 individuals worldwide, collecting nuanced attention benchmarks that offer invaluable insight into how content is consumed across various devices, channels, platforms, and formats. Activated within Omni, these datasets have enabled more precise channel selection tailored to the attention needs of individual campaigns.
“With the addition of the Lumen data, planning teams across OMG will have greater visibility into the attention value that each channel and format generates for their clients, ensuring optimal delivery of the right level of attention based on brand, brief and budget,” says OMG EMEA CEO Dan Clays.
Adds Mike Follett, CEO of Lumen, “The combination of Lumen’s attention data with OMG’s best-in-class Omni channel planning capabilities translates to a significant leap forward in leveraging attention to drive better outcomes for marketers.”
About Omnicom Media Group Omnicom Media Group (OMG), the media services division of Omnicom Group Inc. (NYSE: OMC), delivers transformational experiences for consumers, clients, and talent. Powered by the Omni marketing orchestration system, OMG connects best-in-class capabilities that enable our full-service media agencies OMD, PHD and Hearts & Science to deliver more relevant and actionable consumer experiences; more productive and proactive client experiences; and more collaborative and rewarding talent experiences for the more than 24,000 people serving the world’s leading brands in OMG agencies around the globe.
About Lumen ResearchLumen is the world’s leading attention technology company, with large-scale biometric datasets based on real-world and predictive eye-tracking technology that helps brands and agencies plan, buy and optimise media campaigns on the basis of human attention with creative, programmatic, and measurement solutions. Founded in 2013, Lumen is headquartered in London with offices in New York and LA.
View original content:https://www.prnewswire.co.uk/news-releases/omnicom-media-group-expands-its-partnership-with-lumen-further-advancing-attention-based-planning-capabilities-across-its-regions-302154915.html
Artificial Intelligence
Picus Security Launches Security Validation for Kubernetes
Teams can eliminate container security exposures with the new enhancements in Picus’ platform for multi-cloud
SAN FRANCISCO, May 23, 2024 /PRNewswire/ — Picus Security, the Security Validation company, today announced security validation for Kubernetes. This new capability allows Security and DevOps teams to realize the benefits of containers securely by proactively measuring and optimizing the resilience of clusters. It is the latest innovative addition to the Picus Security Validation Platform, which empowers users to consistently validate their security posture and measure risk across on-premises and multi-cloud environments.
For organizations that want an agile way to deploy, run and scale applications, Kubernetes offers considerable benefits. However, security is often the biggest barrier to its adoption. The dynamic and complex nature of Kubernetes means that containers are often misconfigured due to human error. Without a hands-on approach to governance, security gaps can easily emerge over time, increasing the risk of incidents. This situation is exacerbated by the high level of expertise required to secure Kubernetes and the use of default settings which are inherently insecure. According to The State of Kubernetes Report, more than two-thirds of Kubernetes users (67%) have delayed deployments due to security concerns.*
The addition of Kubernetes validation extends the Picus platform’s existing validation capabilities, which are powered by attack simulation and GenAI. It enables organizations to proactively identify and mitigate security misconfigurations, such as weak policies and settings that could allow containers to run with insecure privileges and facilitate lateral movement. Now security teams can automatically assess the security of their workloads wherever they are located – on-premises, in containers, and also in cloud platforms including Amazon Web Services, Google Cloud Platform, and Microsoft Azure.
“Cloud security is perhaps the biggest barrier of entry for organizations that want to take advantage of container orchestration,” said Volkan Erturk, Picus CTO and Co-Founder. “Kubernetes offers incredible opportunities for DevOps teams to deploy and scale new applications, but Security teams can struggle to keep pace.
“With the Picus Security Validation Platform, security concerns won’t slow down an organization’s digital transformation journey. This new offering will allow our users to consistently measure the security of their workloads and vastly reduce the effort needed to address exposures across growing IT environments.”
Additional Information
Read the Kubernetes validation announcement blog.Register for the upcoming webinar on July 11th 2024 at 10.00 EST/ 15.00 BST: Beyond Cloud Security Posture Management: Validating Cloud Effectiveness with Attack Simulation About Picus Security
Picus Security helps security teams consistently and accurately validate their security posture. Our Security Validation Platform simulates real-world threats to evaluate the effectiveness of security controls, identify high-risk attack paths to critical assets, and optimize threat prevention and detection capabilities.
As the pioneer of Breach and Attack Simulation, we specialize in delivering the actionable insights our customers need to be threat-centric and proactive.
Picus is a Gartner® Peer Insights™ Customers’ Choice for 2024 in the BAS tools category†. The company is recognized as a leader by Frost & Sullivan^.
† Gartner, Voice of the Customer for Breach and Attack Simulation Tools, Peer Contributors, 30 January 2024 ^ Frost and Sullivan, 2022 Frost Radar™ report for the Global Breach and Attack Simulation Market
Logo: https://mma.prnewswire.com/media/2183222/4724563/Picus_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/picus-security-launches-security-validation-for-kubernetes-302154775.html
-
Uncategorized7 days ago
Coca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence7 days ago
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Uncategorized7 days ago
The rise of intelligent automation as a strategic differentiator
-
Uncategorized7 days ago
AI, bias and experiments: how Women in News is tackling tech’s inbuilt stereotypes
-
Uncategorized7 days ago
Sony Music slams tech giants for unauthorised use of stars’ songs
-
Uncategorized7 days ago
Sainsbury’s aims to be an ‘AI-enabled grocer’ with Microsoft AI technology
-
Uncategorized7 days ago
How SAP BTP Becomes the Trusted Platform for Business AI
-
Uncategorized7 days ago
Researchers build AI-driven sarcasm detector